Newly Diagnosed RRMS Patients Should Avoid Lemtrada and Look to Other Less Toxic Treatments

Lemtrada Stroke Lawsuit News

Lemtrada infusion should be reserved as a last resort and used only when all other alternatives fail

Wednesday, March 11, 2020 - People suffering from relapse remitting multiple sclerosis are constantly faced with the decision as to which disease-modifying drug to take and may get discouraged when one drug after another seems to fail and the severity and duration of their RRMS symptoms return possibly even more severe than the last. I have written at length about Lemtrada, a drug of last resort that can be very effective in managing RRMS symptoms, but also a drug that has the most severe potential side effects including instant, sudden death within 24-hours of the drug's infusion or even as suddenly as during treatments. For the record, Lemtrada causes arterial dissection that lead to paralyzing strokes and sudden death from heart attack, however, RRMS symptoms can progress and become so severe that patients that have lost all hope in any other drug are willing to risk their lives for the hope that they may be able to lead a relatively normal life if for even a short while of a year or two more before totally surrendering to the disease. Patients with severe RRMS hold out hope that a cure will someday be found or another more effective disease-modifying drug may be found. If you have been recently diagnosed with RRMS for the first time you may want to know which drugs are available to you and experiment gradually, taking only the least potent treatments, to begin with. Lemtrada stroke lawsuit attorneys offer a no obligation free consultation to families and individuals nationwide.

Newly diagnosed RRMS patients with active symptoms consider taking Copaxone to manage their symptoms and the drug may make those symptoms less frequent and less severe than taking no drug at all. According to MS, a trusted source of information for RRMS sufferers, "Copaxone is a moderately effective (category 1.1) DMD; in clinical trials, people taking Copaxone had about 30% fewer relapses than people taking placebo. In clinical trials, MRI scans showed people taking Copaxone had fewer, smaller or no new areas of active MS (lesions)." Copaxone is available through a neurologist by prescription and is to be self-injected three times per week. The drug comes in pre-measured, pre-filled syringes to make the administration of the drug as straightforward as possible. Your doctor or neurological nurse may teach you how to inject yourself. The side effects of Copaxone are somewhat mild but must be considered and taken seriously.

Common side effects include injection site reactions such as lipoatrophy (leading to permanent indentations in the skin), redness, swelling, itching or some pain at the site. MS Trust points out the one problem that Copaxone patients should anticipate: "Occasionally, some people may experience a reaction, known as the immediate post-injection reaction (IPIR), shortly after injection. This may cause flushing, chest tightness, shortness of breath and palpitations. This reaction can last 15-30 minutes, will ease without any treatment and doesn't cause long-term problems."

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.